drugset / Trial / NCT00049946

Schizophrenia Study In Adults

NCT00049946

Phase 2 Completed 231 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

A Placebo Controlled Study For Patients With Schizophrenia

Timeline

Start
2002-10
Primary completion
2003-04
Completion
2003-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Risperidone Other / unclassified
Subject talnetant Small molecule

Indications